Josef Bogenschuetz joins Novalung as Managing Director

Novalung GmbH prepares for further growth with former Maquet CEO.

As of January 1, 2011, Josef Bogenschütz and Dr. Georg Matheis are joint Managing Directors of Novalung GmbH. Bogenschütz will be specifically responsible for Research & Development, Manufacturing, Quality Management and Finance. This addition underscores the company’s focus on the ongoing and efficient expansion of its portfolio of innovative products designed to replace invasive mechanical ventilation. Nicholas L. Strout remains responsible for the growth of Novalung’s sales activities.

Dr. Georg Matheis, who has been Managing Director of Novalung since its founding in 2003, commented: “I’m truly looking forward to working with Josef Bogenschütz, who brings with him extensive expertise in our core business, the development and manufacturing of artificial lungs.“

Josef Bogenschütz worked together with Georg Matheis at the German company Jostra AG in the field of cardiac surgery before Jostra was sold to Maquet Cardiopulmonary AG eight years ago and Novalung GmbH was spun off as an independent company. During their time together they laid the foundation for the development of the iLA Membrane Ventilator, Novalung’s flagship product for innovative ventilation therapy. “Since that time I have followed Novalung‘s development with great interest“, Bogenschütz says. “Having built up and developed the Cardiopulmonary business at Maquet over the past several years, I am excited at the prospect of using my experience and focus to drive the development and positioning of Novalung as an innovative company in the field of ventilation.” Bogenschütz explains his decision to move to Novalung after eight years at Maquet with his motto: “You have to have a vision for the future to be able to change the present.”

Bogenschütz was most recently President and CEO at Maquet Cardiopulmonary AG. The 45-year-old mechanical engineer began his career in manufacturing management at Bizerba GmbH and Beru AG before entering the medical device field 11 years ago when he joined Jostra AG.

Background information

Objective: Replacing the invasive mechanical ventilation
Novalung‘s mission is to create new solutions for the treatment of lung failure with innovative artificial lungs that “breathe” outside the patient’s body. Instead of placing patients in an artificial coma so that they can tolerate mechanical ventilation Novalung products allow patients being awake and to breathe easily and spontaneously. Those innovative technologies open the door for physicians and nurses to the vision of replacing the damaging invasive mechanical ventilation.

Novalung GmbH
Novalung GmbH was founded in Hechingen (Baden-Württemberg, Germany) in 2003 through the fusion of leading German and American technologies in the field of artificial lungs and is now active throughout the world. From the outset Novalung has focused on high-quality development and production “Made in Germany“. Cutting-edge technologies are employed in Novalung’s medtech production facility in the manufacture in particular of the iLA Membrane Ventilator® and NovaPort® vascular access cannulas, both of which have been used to help treat thousands of patients.

The privately funded Novalung GmbH is a fast growing medical technology company based in the area of Heilbronn/Germany and a subsidiary on the campus of the University of Michigan at Ann Arbor, USA.

Mrs Franziska Preissing
Head of Marketing
franziska.preissing@novalung.com

Novalung GmbH
Im Zukunftspark 1
DE-74076 Heilbronn
Germany

T. +49 7131 27 06 130
F. +49 7131 27 06 230
M. +49 173 659 85 63
www.novalung.com/media

This release was published on openPR.